AN-7 is an orally active histone deacetylase (HDAC) inhibitor that induces histone hyperacetylation and differentiation, and inhibits the proliferation of human prostate 22Rv1 cancer cells in vitro and in vivo; it upregulates the expression of the pro-apoptotic protein Bax, downregulates the anti-apoptotic protein Bcl-2, and promotes apoptosis through activation of caspase-3, making it useful for prostate cancer research.